|Nom||Titre||Payer||Exercé||Année de naissance|
|Mr. Daniel E. Cohen||Director||319,3k||S.O.||1953|
|Mr. Hugo Brugiere M.Sc.||CEO & Chairman||S.O.||S.O.||S.O.|
|Mr. Ilya Chumakov Ph.D., D-Sc||Co-Founder, Chairman of Scientific Advisory Board and Director||S.O.||S.O.||S.O.|
|Dr. Rob Quinn Ph.D.||Chief Financial Officer||S.O.||S.O.||1983|
|Mr. Xavier Paoli M.Sc.||Chief Operating Officer||S.O.||S.O.||S.O.|
|Mr. Antoine Gravelle||Gen. Counsel||S.O.||S.O.||S.O.|
|Ms. Susanne Dorn||Chief Regulatory Officer||S.O.||S.O.||S.O.|
|Mr. Rodolphe Hajj||Chief Pharmacology Officer||S.O.||S.O.||S.O.|
|Ms. Viviane Bertrand||Chief Preclinical Drug Devel. Officer||S.O.||S.O.||S.O.|
|Mr. Philippe Rinaudo||Chief Data Science Officer||S.O.||S.O.||S.O.|
Pharnext SA, a clinical-stage biopharmaceutical company, develops therapies for orphan and common neurodegenerative diseases in France. The company's products include SYNGILITY that has completed Phase III trial for the treatment of Charcot-Marie-Tooth disease type 1A; and PXT864, which has completed Phase II clinical trial to treat Alzheimer's disease, as well as Parkinson's disease and amyotrophic lateral sclerosis. It also develops PLEOTHERAPY, a big genetic data and artificial intelligence platform. Pharnext SA has an agreement with the University Hospital Institute Mediterranee Infection to evaluate repurposed drugs for potential use against the COVID-19 virus. The company was founded in 2007 and is headquartered in Issy-Les-Moulineaux, France.
L’ISS Governance QualityScore de Pharnext SA en date du S.O. est S.O.. Les scores principaux sont Audit : S.O.; Société : S.O.; Droits des actionnaires : S.O.; Compensation : S.O..